Sonic Fund Ii, L.P. Adverum Biotechnologies, Inc. Transaction History

Sonic Fund Ii, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	BUY	$3.36 - $10.56 $22 Million - $69.2 Million	6,552,068 New	6,552,068 $22.9 Million
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $22 Million - $69.2 Million	-6,552,068 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$9.26 - $14.36 $13.4 Million - $20.8 Million	1,450,281 Added 28.43%	6,552,068 $64.6 Million
Q4 2020 Feb 16, 2021	BUY	$9.84 - $14.26 $9.76 Million - $14.1 Million	991,920 Added 24.14%	5,101,787 $55.3 Million
Q3 2020 Nov 16, 2020	SELL	$10.3 - $21.64 $25,626 - $53,840	-2,488 Reduced 0.06%	4,109,867 $42.3 Million
Q1 2020 May 15, 2020	BUY	$7.98 - $16.32 $551,761 - $1.13 Million	69,143 Added 1.71%	4,112,355 $40.2 Million
Q4 2019 Feb 14, 2020	BUY	$5.12 - $12.22 $20.7 Million - $49.4 Million	4,043,212 New	4,043,212 $46.6 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Sonic Fund Ii, L.P., based on Form 13F filings with the SEC.

Stay updated on Sonic Fund Ii, L.P. with notifications on news.